Immutep Ltd (ASX:IMM) Share Price Climbs: Key Reasons Explained

Sonal Goyal

11 November 2026 01:16 PM AEDT

Immutep Ltd (ASX:IMM) Share Price Climbs: Key Reasons Explained

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Immutep shares traded up 8.33% at $0.026 during the 11 November 2026 trading session.
The company was granted US Patent number 12,788,796 for combined preparations of efti with PD-1 pathway inhibitors.
The patent expires on 23 March 2038, including 806 days of patent term adjustment.

During the Trading session on 11 November 2026, Immutep Ltd (ASX:IMM) shares were trading at $0.026 by late morning, up 8.33%. The S&P/ASX 200 (ASX:XJO) was down about 0.06% at 9,123.90 at 12:19 pm over the same period. Immutep is a biotechnology company developing novel immunotherapies and is listed on both the ASX and NASDAQ. On 11 November 2026, the company announced the grant of a new United States patent, which was disclosed on the same day as the trading move.

New US Patent Grant

On 11 November 2026, Immutep said the United States Patent and Trademark Office had granted patent number 12,788,796, titled Combined Preparations for the Treatment of Cancer or Infection. The company now holds five US patents within this family, following earlier grants in December 2020, March 2021, June 2023 and July 2026.

Claims and Scope

The company said the claims are directed to combined preparations and pharmaceutical compositions comprising eftilagimod alfa, known as efti, and a PD-1 pathway inhibitor. The claims specifically cover combinations with BMS-936559, durvalumab, atezolizumab and avelumab. Immutep also said it has filed a continuation application to pursue additional embodiments of the invention.

Patent Expiry

The patent expires on 23 March 2038, including 806 days of patent term adjustment. The company described the grant as providing additional protection for the use of efti in combination with PD-1 pathway inhibitors.

Sector Context

Patent protection is a central part of biotechnology Business models, particularly for companies developing immunotherapies. Combination therapies with established immunotherapy classes are a major area of drug development, and investors often follow intellectual property developments closely when assessing companies at the clinical stage.

Key Risks

A patent grant does not by itself confirm the commercial success of a therapy, and Immutep’s clinical programs remain subject to trial outcomes and regulatory processes. Patent claims can also be challenged, and the company will require ongoing funding to advance its development programs. Biotechnology shares at low prices can be volatile.

What to Watch Ahead

Investors will be watching the progress of the continuation application and any further patent grants in the portfolio. Clinical trial updates for efti-based combination programs and the company’s next Quarterly Report will also be relevant to the company’s development path.

Final Word

Immutep’s trading session on 11 November 2026 coincided with the announcement of a new US patent grant for its efti-based combination therapies. The company’s clinical progress will determine how the expanded patent estate is used in the years ahead.

FAQs

Q: What patent did Immutep receive?

A: The United States Patent and Trademark Office granted patent number 12,788,796, covering combined preparations of efti with PD-1 pathway inhibitors.

Q: When does the patent expire?

A: The patent expires on 23 March 2038, including 806 days of patent term adjustment.

Q: How many US patents does Immutep now hold in this family?

A: The company now holds five United States patents within this patent family.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.